BLING III — Continuous vs Intermittent β-Lactam Antibiotic Infusions

TL;DR: 🟡 Borderline, likely beneficial — continuous beta-lactam infusion trended toward lower mortality (P=0.08, didn't reach significance) with a significant clinical-cure benefit; concordant with prior trials and meta-analysis.

1. Publication

• Title: Continuous vs Intermittent β-Lactam Antibiotic Infusions in Critically Ill Patients With Sepsis: The BLING III Randomized Clinical Trial
• Acronym: BLING III
• Year & Journal: JAMA, published June 12, 2024 (332(8):629-637)
• Citation: Dulhunty JM, Brett SJ, De Waele JJ, et al; BLING III Study Investigators and ANZICS CTG. JAMA. 2024;332(8):629-637. doi:10.1001/jama.2024.9779

2. Context & Rationale

Background: Beta-lactam antibiotics have time-dependent bactericidal activity; continuous infusion theoretically improves antibiotic exposure (longer time above MIC), potentially improving bacterial eradication, especially given altered pharmacokinetics in sepsis (increased clearance, capillary leak). Prior BLING II (2015) found no difference in ICU-free days; MERCY (2023) found a non-significant 2% mortality reduction with continuous meropenem — setting up this larger, definitive test.

Research Question/Hypothesis: In critically ill adults with sepsis, does continuous infusion of beta-lactam antibiotics (piperacillin-tazobactam or meropenem) reduce 90-day mortality compared with intermittent infusion?

3. Design & Methods

• Study Type: Prospective, multicenter, open-label, phase III RCT
• Population: Critically ill adults with sepsis on piperacillin-tazobactam or meropenem
• Intervention: Continuous infusion, up to 14 days
• Comparator: Intermittent infusion (30-min infusion), same duration
• Statistical Power & Follow-Up: Primary: 90-day all-cause mortality. Secondary: clinical cure at day 14.

4. Key Results

Interpretive note (per authors' own press release): "The observed difference in 90-day mortality... did not meet statistical significance in the primary analysis. However, the confidence interval around the effect estimate includes the possibility of both no important effect and a clinically important benefit."

5. Internal Validity Assessment

Large, multicenter, open-label phase III RCT. Overall: Strong — the confidence interval, while not excluding null, is consistent with a potentially important clinical benefit; the significant secondary clinical-cure endpoint provides supportive (though not definitive, given multiplicity concerns) corroboration.

6. External Validity Assessment

Multicenter, international ICU sepsis population on standard beta-lactam agents (piperacillin-tazobactam, meropenem) — broadly representative and directly relevant given how commonly these agents are used.

7. Strengths & Limitations

Strengths: Largest, most definitive test of this long-debated question; builds directly on BLING II and MERCY, with concordant directional findings across all three; both primary (mortality) and secondary (clinical cure) outcomes point the same direction.

Limitations: Open-label design; primary endpoint technically did not reach significance (P=0.08); a JAMA companion meta-analysis and editorial specifically address how to interpret this "borderline" result.

8. Interpretation & Practice Impact

Provides "important evidence to guide antibiotic management," per the lead investigator — while not definitively proving a mortality benefit, the totality of evidence (BLING II, MERCY, BLING III, meta-analysis) increasingly supports continuous infusion as the preferred approach for beta-lactam dosing in ICU sepsis.

9. Controversies & Subsequent Evidence

An accompanying JAMA editorial ("Resolving the Dilemma on Continuous vs Intermittent β-Lactam Antibiotic Infusions," Wiersinga, van Agtmael) and a concurrently published systematic review/meta-analysis (Abdul-Aziz et al., JAMA 2024;332(8):638-648) pooling BLING III with prior trials help contextualize this "borderline significant" result within the broader evidence base, generally supporting continuous infusion as likely beneficial despite the individual trial not reaching its own significance threshold.

10. Summary & Executive Takeaway

Summary: BLING III randomized critically ill sepsis patients to continuous or intermittent beta-lactam infusion. 90-day mortality trended lower with continuous infusion (absolute difference −1.9%, 95% CI −4.9 to 1.1, P=0.08) — not statistically significant but consistent with a clinically important benefit — with significantly higher clinical cure at day 14.

Overall Takeaway: BLING III did not definitively prove a mortality benefit from continuous beta-lactam infusion, but its confidence interval, concordant secondary outcome, and consistency with prior trials (BLING II, MERCY) and a companion meta-analysis collectively support continuous infusion as a likely beneficial, low-risk practice change for ICU sepsis management.

11. Bibliography

• Monti G, Bradić N, Mazzaroli M, et al; MERCY Investigators. Continuous vs intermittent meropenem administration (MERCY). JAMA. 2023;330(2):141-151.
• Abdul-Aziz MH, Hammond NE, Brett SJ, et al. Prolonged vs Intermittent Infusions of β-Lactam Antibiotics: Systematic Review and Meta-Analysis. JAMA. 2024;332(8):638-648.
• Wiersinga WJ, van Agtmael MA. Resolving the Dilemma on Continuous vs Intermittent β-Lactam Antibiotic Infusions [editorial]. JAMA. 2024;332(8):623-624.